**Appendix**

The CHeCS Investigators include the following investigators and sites: Scott D. Holmberg, Eyasu H.Teshale, Philip R. Spradling, Anne C. Moorman, Jian Xing, and Xin Tong, Division of Viral Hepatitis, National Centers for HIV, Viral Hepatitis, STD, and TB Prevention (NCHHSTP), Centers for Disease Control and Prevention (CDC), Atlanta, Georgia; Stuart C. Gordon, David R. Nerenz, Mei Lu, Lois Lamerato, Loralee B. Rupp, Nonna Akkerman, Nancy Oja-Tebbe, Chad M. Cogan, and Dana Larkin, Henry Ford Health System, Detroit, MI; Joseph A. Boscarino, Zahra S. Daar, Joe B. Leader, and Robert E. Smith, Geisinger Health System, Danville, PA; Cynthia C. Nakasato, Vinutha Vijayadeva, Kelly E. Sylva, John V. Parker, and Mark M. Schmidt, Kaiser Permanente Hawaii, Honolulu, HI; Mark A. Schmidt, Judy L. Donald, and Erin M. Keast, Kaiser Permanente Northwest, Portland, OR.

**Appendix Table 1.** Codes Used for Analysis of Cancer Incidence (ICD-O-3/Morphology) and Cancer-related Mortality (ICD-10) Among Chronic HCV-infected Persons (CHeCS) Compared to SEER or MCOD,\* 2006-2010



\*Cancers with 5 or more observed cases

†International Classification of Diseases for Oncology, 3rd Revision codes and corresponding morphology codes, specifying cancer site and histological diagnosis, were used to generate SEER-recode variables for comparison to SEER\*Stat generated SEER Registry SEER-recode variables.

‡§International Classification of Diseases, 10th Revision was used for mortality comparisons between CHeCS and MCOD.